Deschloroclozapine exhibits an exquisite agonistic effect at lower concentration compared to clozapine-N-oxide in hM3Dq expressing chemogenetically modified rats

IntroductionWithin the realm of chemogenetics, a particular form of agonists targeting designer receptors exclusively activated by designer drugs (DREADDs) has emerged. Deschloroclozapine (DCZ), a recently introduced DREADDs agonist, demonstrates remarkable potency in activating targeted neurons at...

Description complète

Détails bibliographiques

Auteurs principaux:	Makiko Shimizu, Mitsuhiro Yoshimura, Kazuhiko Baba, Naofumi Ikeda, Yuki Nonaka, Takashi Maruyama, Tatsushi Onaka, Yoichi Ueta
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2023-11-01
Collection:	Frontiers in Neuroscience
Sujets:	deschloroclozapine clozapine-N-oxide DREADDs oxytocin central nervous system Fos
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fnins.2023.1301515/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!